Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
triple-negative breast cancer
Biotech
Puma pounces on failed Takeda drug, snapping up cancer prospect
Puma landed a global license for $7 million upfront, plus up to $287.3 million in milestones, and plans to target breast and small cell lung cancer.
Nick Paul Taylor
Sep 21, 2022 9:05am
CytomX puts lead ADC on the block after phase 2 data underwhelm
Jul 7, 2022 8:45am
An mRNA therapy might boost response to I-O in breast cancer
Mar 22, 2022 9:10am
Heart arrhythmia drug reduces tumor spread in cancer mouse model
Jan 18, 2022 8:55am
Sanofi inks $270M cancer AI deal with developer Owkin
Nov 18, 2021 1:30am
Targeting tumor-driving RNA proteins in aggressive breast cancer
Jul 2, 2021 11:00am